Detalhe da pesquisa
1.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Ann Oncol
; 31(3): 377-386, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32067679
2.
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
Invest New Drugs
; 38(2): 402-409, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30953269
3.
Novel patterns of response under immunotherapy.
Ann Oncol
; 30(3): 385-396, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30657859
4.
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Ann Oncol
; 30(8): 1381-1392, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31114846
5.
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
Ann Oncol
; 29(9): 1911-1917, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30060061
6.
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
Ann Oncol
; 29(12): 2313-2327, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30307465
7.
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.
Ann Oncol
; 29(1): 30-35, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29140430
8.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.
Ann Oncol
; 28(3): 590-596, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27993804
9.
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Ann Oncol
; 28(7): 1605-1611, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419181
10.
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study.
Eur J Cancer Care (Engl)
; 26(6)2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27734561
11.
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.
Br J Cancer
; 114(11): 1199-205, 2016 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27140316
12.
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials.
Ann Oncol
; 26(9): 1808-1812, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26088197
13.
Designs of drug-combination phase I trials in oncology: a systematic review of the literature.
Ann Oncol
; 26(4): 669-674, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25403591
14.
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.
Ann Oncol
; 26(2): 422-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25403589
15.
Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.
Ann Oncol
; 26(12): 2419-28, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26371283
16.
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.
Br J Cancer
; 111(1): 17-24, 2014 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24762958
17.
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.
Ann Oncol
; 24(3): 761-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23108949
18.
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.
ESMO Open
; 8(4): 101616, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37542912
19.
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.
ESMO Open
; 8(4): 101610, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37536254
20.
Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents.
Br J Cancer
; 106(5): 854-7, 2012 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22281665